Cited by 281Substance Abuse Treatment and OutcomesOpioid Use Disorder TreatmentNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Bupropion and Naltrexone in Methamphetamine Use Disorder

Open access

Trivedi, Madhukar H., Walker, Robrina, Ling, Walter, dela Cruz, Adriane, Sharma, Gaurav, Carmody, Thomas, Ghitza, Udi E., Wahle, Aimee, Kim, Mora, Shores-Wilson, Kathy, Sparenborg, Steven, Coffin, Phillip, Schmitz, Joy, Wiest, Katharina, Bart, Gavin, Sonne, Susan C., Wakhlu, Sidarth, Rush, A. John, Nunes, Edward V., Shoptaw, Steven·2021·New England Journal of Medicine

DOI 10.1056/nejmoa2020214PMC PMC8111570

Open this paper in CoChat — free account

Abstract

BACKGROUND: The use of naltrexone plus bupropion to treat methamphetamine use disorder has not been well studied. METHODS: We conducted this multisite, double-blind, two-stage, placebo-controlled trial with the use of a sequential parallel comparison design to evaluate the efficacy and safety of extended-release injectable naltrexone (380 mg every 3 weeks) plus oral extended-release bupropion (450 mg per day) in adults with moderate or severe methamphetamine use disorder. In the first stage of the trial, participants were randomly assigned in a 0.26:0.74 ratio to receive naltrexone-bupropion or matching injectable and oral placebo for 6 weeks. Those in the placebo group who did not have a response in stage 1 underwent rerandomization in stage 2 and were assigned in a 1:1 ratio to receive naltrexone-bupropion or placebo for an additional 6 weeks. Urine samples were obtained from participants twice weekly. The primary outcome was a response, defined as at least three methamphetamine-negative urine samples out of four samples obtained at the end of stage 1 or stage 2, and the weighted average of the responses in the two stages is reported. The treatment effect was defined as the between-group difference in the overall weighted responses. RESULTS: A total of 403 participants were enrolled in stage 1, and 225 in stage 2. In the first stage, 18 of 109 participants (16.5%) in the naltrexone-bupropion group and 10 of 294 (3.4%) in the placebo group had a response. In the second stage, 13 of 114 (11.4%) in the naltrexone-bupropion group and 2 of 111 (1.8%) in the placebo group had a response. The weighted average response across the two stages was 13.6% with naltrexone-bupropion and 2.5% with placebo, for an overall treatment effect of 11.1 percentage points (Wald z-test statistic, 4.53; P<0.001). Adverse events with naltrexone-bupropion included gastrointestinal disorders, tremor, malaise, hyperhidrosis, and anorexia. Serious adverse events occurred in 8 of 223 participants (3.6%) who received naltrexone-bupropion during the trial. CONCLUSIONS: Among adults with methamphetamine use disorder, the response over a period of 12 weeks among participants who received extended-release injectable naltrexone plus oral extended-release bupropion was low but was higher than that among participants who received placebo. (Funded by the National Institute on Drug Abuse and others; ADAPT-2 ClinicalTrials.gov number, NCT03078075.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2020214

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
Methamphetamine: An update on epidemiology, pharmacology, clinical phenomenology, and treatment literature
Courtney, K. E., & Ray, L. A. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.08.003 · Cited by 502
The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design Approach
Fava, M., Evins, A. E., Dorer, D. J., & Schoenfeld, D. A. (2003) · Psychotherapy and Psychosomatics · doi:10.1159/000069738 · Cited by 452
Methamphetamine use: A comprehensive review of molecular, preclinical and clinical findings
Panenka, W. J., Procyshyn, R. M., Lecomte, T., MacEwan, G. W., Flynn, S. W., Honer, W. G., & Barr, A. M. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.11.016 · Cited by 432
Twin epidemics: The surging rise of methamphetamine use in chronic opioid users
Ellis, M. S., Kasper, Z. A., & Cicero, T. J. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.08.029 · Cited by 360
Association of Stimulant Use With Dopaminergic Alterations in Users of Cocaine, Amphetamine, or Methamphetamine: A Systematic Review and Meta-analysis
Ashok, A. H., Mizuno, Y., Volkow, N. D., & Howes, O. D. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0135 · Cited by 330
Bupropion for the treatment of methamphetamine dependence
Elkashef, A. M., Rawson, R. A., Anderson, A. L., Li, S.-H., Holmes, T., Smith, E. V., Chiang, N., Kahn, R., Vocci, F., Ling, W., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301481 · Cited by 234
Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review
Siefried, K. J., Acheson, L. S., Lintzeris, N., & Ezard, N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00711-x · Cited by 194
Naltrexone for the Treatment of Amphetamine Dependence: A Randomized, Placebo-Controlled Trial
Jayaram-Lindström, N., Hammarberg, A., Beck, O., & Franck, J. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08020304 · Cited by 185
Bupropion Reduces Methamphetamine-Induced Subjective Effects and Cue-Induced Craving
Newton, T. F., Roache, J. D., Garza, R. D. L., FONG, T. W., Wallace, C. L., Li, S.-H., Elkashef, A. M., Chiang, N., & Kahn, R. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300979 · Cited by 163

Show all 30 references

Sorted by citations

Items 101–200 of 279

Centering peers in design and training for a peer-delivered contingency management program for self-identified harm reduction and treatment goals
Peng, L., Stack, E., Cooke, A. C., Hartzler, B. J., Cook, R., Leichtling, G. J., Hildebran, C., Leahy, J. M., Payne, K. S., Kunkel, L. E., et al. (2025) · Harm Reduction Journal · doi:10.1186/s12954-025-01213-z · Cited by 7
Effects of methamphetamine-induced neurotoxicity on striatal long-term potentiation
Gibson, A. S., West, P. J., & Keefe, K. A. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06055-8 · Cited by 7
Disposition, outcomes, and lengths of stay due to bupropion overdose at a tertiary care center with a medical toxicology service
Mccabe, D. J., Radke, J. B., & Wilson, B. Z. (2022) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2022.02.025 · Cited by 7
Modafinil does not reduce cocaine use in methadone-maintained individuals
DeVito, E. E., Poling, J. C., Babuscio, T. A., Nich, C., Carroll, K. M., & Sofuoglu, M. (2022) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2022.100032 · Cited by 6
Transcranial Magnetic Stimulation for Methamphetamine Use Disorder: A Scoping Review within the Neurocircuitry Model of Addiction
Ballester, J., Marchand, W. R., & Philip, N. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115995 · Cited by 7
Narcotics Anonymous members in recovery from methamphetamine use disorder
Galanter, M. S., White, W. L., & Hunter, B. D. (2022) · American Journal on Addictions · doi:10.1111/ajad.13362 · Cited by 7
Caring for Hospitalized Adults with Methamphetamine Use Disorder: A Proposed Clinical Roadmap
Priest, K. C., Balasanova, A. A., Levander, X. A., Chan, B. L., Blazes, C. K., Mahan, J. D., Brown, J. A., Mahoney, S., Peng, L., Mahoney, S., et al. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.01.012 · Cited by 7
Methamphetamine‐associated cardiomyopathy: an addiction medicine perspective
Somma, V., Osekowski, M., Paratz, E. D., & Bonomo, Y. A. (2023) · Internal Medicine Journal · doi:10.1111/imj.15990 · Cited by 6
Artificial intelligence‐based drug repurposing with electronic health record clinical corroboration: A case for ketamine as a potential treatment for amphetamine‐type stimulant use disorder
Gao, Z., Winhusen, T. M., Gorenflo, M. P., Dorney, I., Ghitza, U. E., Kaelber, D. C., & Xu, R. (2024) · Addiction · doi:10.1111/add.16715 · Cited by 8
Self-citation
Therapeutic targeting of neuroinflammation in methamphetamine use disorder
Jeffery, N., Mock, P. Y., Yang, K., Tham, C. L., Israf, D. A., Li, H., Wang, X., & Lam, K. W. (2024) · Future Medicinal Chemistry · doi:10.1080/17568919.2024.2447226 · Cited by 7
Bupropion Slow Release vs Placebo With Adaptive Incentives for Cocaine Use Disorder in Persons Receiving Methadone for Opioid Use Disorder
Ware, O. D., Sweeney, M. M., Cunningham, C. J., Umbricht, A., Stitzer, M. L., & Dunn, K. E. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.2278 · Cited by 6
Case Report: Unusual oral cavity changes associated with methamphetamine abuse
Скрипник, М. І., Skrypnyk, R. І., Петрушанко, Т. О., Skikevych, M., Petrushanko, V., & Скрипник, І. М. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1473584 · Cited by 6
The application of harm reduction to methamphetamine use during pregnancy: a call to arms
Wakeman, B., Kremer, M. E., & Schulkin, J. A. (2021) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2021.100418 · Cited by 7
Different drugs, different sides: injection use of opioids alone, and not stimulants alone, predisposes to right-sided endocarditis
Johnstone, R., Khalil, N., Shojaei, E., Puka, K., Bondy, L., Koivu, S. L., & Silverman, M. (2022) · Open Heart · doi:10.1136/openhrt-2021-001930 · Cited by 6
Percentage of Negative Urine Drug Screens as a Clinically Meaningful Endpoint for RCTs Evaluating Treatment for Cocaine Use
Loya, J. M., Babuscio, T., Nich, C., Alessi, S. M., Rash, C. J., & Kiluk, B. D. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.109947 · Cited by 6
Executive Function and Contingency Management in Methamphetamine Use Disorder.
van Nunen, L. J., Lake, M. T., Ipser, J., Stein, D. J., SHOPTAW, S. J., & London, E. D. (2021) · PubMed · Cited by 6
Self-citation
Behavioral Risk Factors for HIV Infection in Hospitalized Persons Who Co-use Stimulants and Opioids
Jawa, R., Stein, M. D., Anderson, B. J., Liebschutz, J. M., Stewart, C., Phillips, K. T., & Barocas, J. A. (2021) · AIDS and Behavior · doi:10.1007/s10461-021-03460-0 · Cited by 6
Treatment Initiation, Substance Use Trajectories, and the Social Determinants of Health in Persons Living With HIV Seeking Medication for Opioid Use Disorder
Cook, R., Jaworski, E., Hoffman, K. A., Waddell, E. N., Myers, R., Korthuis, P. T., & Vergara‐Rodriguez, P. (2023) · Substance Abuse · doi:10.1177/08897077231200745 · Cited by 5
Novel potential pharmacological approaches in treating eating disorders comorbid with substance use disorders
Xi, Z., & Galaj, E. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118327 · Cited by 5
Use of Injection Drugs and Any Form of Methamphetamine in the Portland, OR Metro Area as a Driver of an HIV Time–Space Cluster: Clackamas, Multnomah, and Washington Counties, 2018–2020
Walters, J. K., Busy, L., Hamel, C., Junge, K., Menza, T. W., Mitchell, J., Pinsent, T. J., Toevs, K., & Vines, J. (2021) · AIDS and Behavior · doi:10.1007/s10461-021-03522-3 · Cited by 5
The effects of acute oral naltrexone pretreatment on the abuse potential of intranasal methamphetamine, and the relationship between reward/punishment sensitivity and methamphetamine’s effects
Jones, J. D., Mumtaz, M., Vadhan, N. P., Martinez, S., Pramanik, S., Manubay, J. M., Mogali, S., Perez, F., Castillo, F., Kranzler, H. R., et al. (2022) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000671 · Cited by 5
Exploring the performance of during-treatment substance use outcome measures in predicting longer-term psychosocial functioning and post-treatment abstinence
Brandt, L., Hu, M., Nunes, E. V., & Campbell, A. N. C. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.109918 · Cited by 6
Self-citation
Sexual orientation differences among men in a randomized clinical trial of extended-release naltrexone and bupropion for methamphetamine use disorder
Kidd, J. D., Smiley, S. L., Coffin, P. O., Carmody, T. J., LEVIN, F. R., Nunes, E. V., SHOPTAW, S. J., & Trivedi, M. H. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.110899 · Cited by 5
Self-citation
Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone
Tsui, J. I., Campbell, A. N. C., Pavlicová, M., Choo, T.-H. J., Lee, J. D., Cook, R., Shulman, M., Nunes, E. V., & Rotrosen, J. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109469 · Cited by 5
Self-citation
Rapid and Direct Detection of Methamphetamine in Biofluids using a MXene‐Enabled Electrochemical Sensor
Ri, W. A. N. G., Deng, X., Chen, B., Shen, J. Z., Xu, W., Zhu, Y., Zhang, Y., & Yang, H. (2026) · Advanced Science · doi:10.1002/advs.202521857 · Cited by 4
Beyond weight loss: multisystem benefits of obesity medications
Savas, M., Kuckuck, S., Boon, M. R., & van Rossum, E. F. C. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00100-2 · Cited by 4
A gender‐based secondary analysis of the ADAPT‐2 combination naltrexone and bupropion treatment for methamphetamine use disorder trial
Levander, X. A., Carmody, T. J., Cook, R., Potter, J. S., Trivedi, M. H., Korthuis, P. T., & SHOPTAW, S. J. (2023) · Addiction · doi:10.1111/add.16163 · Cited by 4
Self-citation
Psychometric properties of the Treatment Effectiveness Assessment in methamphetamine use disorder
Vo, H. T., Kulikova, A., Mayes, T. L., Carmody, T. J., SHOPTAW, S. J., Ling, W. W., Trombello, J. M., & Trivedi, M. H. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2023.209085 · Cited by 4
Self-citation
Characterising methamphetamine/amphetamine use among opioid agonist therapy‐seeking adults with prescription‐type opioid use disorder in Canada
Langlois, J., Fairbairn, N. S., Jutras‐Aswad, D., Foll, B. L., Lim, R., & Socias, M. E. (2024) · Drug and Alcohol Review · doi:10.1111/dar.13863 · Cited by 4
Effects of a hospital discharge clinic among people with HIV : Lack of early follow‐up is associated with 30‐day hospital readmission and decreased retention in care
Hill, L. A., Thompson, C., Balcombe, S., Jain, S., He, F., Karris‐Young, M., Martin, T., Karim, A., Bamford, L. P., & Deiss, R. (2023) · HIV Medicine · doi:10.1111/hiv.13577 · Cited by 4
No Time to Wait: Leveraging Primary Care to Treat Stimulant Use Disorder
Tilhou, A. S., Baldwin, M., & Alves, J. (2024) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2024.05.005 · Cited by 4
Is Naltrexone Effective and Safe for Treating Amphetamine-Type Stimulant Use Disorder? A Systematic Review and Meta-analysis
Bastien, G., McAnulty, C., Sharafi, H., Mahroug, A., Elkrief, L., Ziegler, D., Dubreucq, S., Juteau, L.-C., & Jutras‐Aswad, D. (2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001422 · Cited by 4
Caring for Patients Using Methamphetamines: An Interprofessional Collaborative Approach.
Kennedy, E. N., Getch, S. E., Grin, B. M., Campillo, R. D., & Niessen, L. C. (2022) · PubMed Central · Cited by 4
Pharmacological Treatment of Substance Use Disorders
Srivastava, A. B., LEVIN, F. R., & Nunes, E. V. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_140-1 · Cited by 4
Self-citation
Drug-detecting bioelectronic nose based on odor cue memory combined with a brain computer interface
Gao, K., Hu, M., Li, J., Li, J., Xu, W., Qian, Z., Gao, F., & Ma, T. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115797 · Cited by 4
The ghost of Heisenberg, or: methamphetamine, again
Price, L. H. (2021) · The Brown University Psychopharmacology Update · doi:10.1002/pu.30718 · Cited by 3
Current State and Understanding of Methamphetamine-associated Pulmonary Arterial Hypertension
(2021) · European Journal of Respiratory Medicine · doi:10.31488/ejrm.112 · Cited by 3
Craving, Impulsivity, and Subsequent Methamphetamine Use With Naltrexone-Bupropion Versus Placebo: Findings From a Randomized Clinical Trial
Jha, M. K., Ghitza, U. E., Carmody, T. J., Kuruvila, S., SHOPTAW, S. J., Minhajuddin, A., Wakhlu, S., Schmitz, J. M., Coffin, P. O., Bart, G. B., et al. (2025) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001538 · Cited by 1
Self-citation
Methamphetamine Pharmacotherapy: A Need to Re-focus on the Complex Neurobiological Changes that Occur Both During and After Methamphetamine Use Disorder
McKetin, R., Kim, J. H., Turner, A., & Berk, M. (2025) · CNS Drugs · doi:10.1007/s40263-025-01214-3 · Cited by 4
The diagnosis and treatment of stimulant-related emergencies
Fries, A., Christ, M., Nickl, H., Spreer, M., Pilhatsch, M., & Petzold, J. (2025) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2025.0158 · Cited by 2
Activation of lateral hypothalamic melanin-concentrating hormone neurons mediates sex-specific patterns of methamphetamine self-administration in rats.
Suarez, M., Kuebler, I. R. K., Schneider, H. M., Vollan, J. D., Hubbard, N. A., & Wakabayashi, K. T. (2025) · Behavioural Brain Research · doi:10.1016/j.bbr.2025.116002 · Cited by 2
Methamphetamine‐Associated Pulmonary Arterial Hypertension: Impact, Mechanisms, and a Framework for Management
Sood, N., Weerasekare, J., Zhyvylo, I., Goncharova, E. A., & Marco, T. D. (2026) · Pulmonary Circulation · doi:10.1002/pul2.70242 · Cited by 2
Overdose risk in the context of chemsex among gay, bisexual, and other men who have sex with men
Duailibe, F. T., Hull, M., Montaner, J., Purdie, A., & Lima, V. D. (2026) · Harm Reduction Journal · doi:10.1186/s12954-026-01410-4 · Cited by 2
Crystal clear: Purity of street-level methamphetamine samples and methamphetamine-adulteration of other drugs in Los Angeles, 2023–2025
Koncsol, A. J., Molina, C. A., Romero, R., Grabill, M., Godvin, M., Carrizal, J., Contreras, M., Arellano, O., Villanueva, N., Jalayer, E., et al. (2026) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2026.100482 · Cited by 2
Evidence-Based Practices for Co-occurring Addiction and Mental Illness
Yuodelis‐Flores, C., Iles-Shih, M., & Ries, R. K. (2022) · Springer eBooks · doi:10.1007/978-3-031-10239-4_25 · Cited by 2
Types of addiction
Turpin, M. A. C., Rowland, K. C., Anugwom, C., Arocha, M., Carona, A., Gonzalez, B. I., Iskander, G., Snyder, S., Wilson, K., Kaye, A. D., et al. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-98814-8.00027-5 · Cited by 3
High suicidality predicts overdose events among people with substance use disorder: A latent class analysis
Schmidt, R. D., Horigian, V. E., Shmueli‐Blumberg, D., Hefner, K. R., Feinberg, J., Kondapaka, R., Feaster, D. J., Duan, R., Gonzalez, S. T., Davis, C., et al. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1150062 · Cited by 2
Off-label medications for addictive disorders
Vanderhoof, T. S. (2023) · Current Psychiatry · doi:10.12788/cp.0384 · Cited by 2
Pharmacist-Driven Alcohol Use Disorder Screening May Increase Inpatient Utilization of Extended-Release Naltrexone: A Single Center Pilot Study
Snyder, S., Butala, N., WILLIAMS, A. M., & Kneebusch, J. (2024) · Pharmacy · doi:10.3390/pharmacy12010026 · Cited by 2
Sociodemographic and patient reported outcomes by racial and ethnicity status among participants in a randomized controlled trial for methamphetamine use disorder
Okafor, C. N., Carmody, T. J., Stotts, A. L., Bart, G. B., Mayes, T. L., Karns-Wright, T., Trivedi, M. H., SHOPTAW, S. J., & Potter, J. S. (2024) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2024.100230 · Cited by 2
Self-citation
Clinical Presentations of Bupropion Prescription Drug Misuse
Noe, G., Shah, K. H., Martin, S. O., & Munjal, S. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001858 · Cited by 2
Disorders due to Substance Use: Stimulants
Sevarino, K. A., & Farrell, M. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_26 · Cited by 3
Managing Stimulant Use Among People With HIV: Harm-Reduction Strategies From Behavior to Medication.
Blair, C. S., & SHOPTAW, S. J. (2024) · PubMed Central · Cited by 2
Self-citation
Glucagon-like peptide-1 receptor activation and mental health: a drug-target mendelian randomization study
Yang, G., Burgess, S., & Schooling, C. M. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04244-7 · Cited by 3
CL Case Conference: Managing Substance Use and Agitation in Pregnancy
Black, J. R., Hovis, E., Spada, M. L., & Li, L. (2025) · Journal of the Academy of Consultation-Liaison Psychiatry · doi:10.1016/j.jaclp.2025.02.002 · Cited by 2
Treatment and Research Needs for Pregnant Individuals With Substance Use Disorders
Guille, C. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20251002 · Cited by 2
Trends in Mortality Due to Stimulants Use in Adolescents and Young Adults
Walia, N., Lat, J., Tariq, R., Tyagi, S., Qazi, A. M., Salari, S. W., Jafar, A., Kousar, T., Renzu, M., Leszkowitz, D., et al. (2021) · Addictive Disorders & Their Treatment · doi:10.1097/adt.0000000000000294 · Cited by 2
Bupropion - an antidepressant drug with broad therapeutic potential
Bróż, S., Dankiewicz, S., Żelazny, P., Filipczak, J., Swora, A., Borowik, J., Sygacz, O., Brodowski, W., Pawłowski, P., & Basta-Arciszewska, K. (2022) · Journal of Education Health and Sport · doi:10.12775/jehs.2022.12.09.070 · Cited by 2
Reconsidering the role of depression and common psychiatric disorders as partners in the type 2 diabetes epidemic
Claro, A. E., Palanza, C., Mazza, M., Rizzi, A., Corsello, A., Tartaglione, L., Marano, G., Schuenemann, G. E. U. M., Rigoni, M., Pontecorvi, A., et al. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i6.1374 · Cited by 2
Methamphetamine Use Among Sexual Minority Men
Lodge, W., Biello, K. B., Valente, P. K., & Mimiaga, M. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-92392-1_109 · Cited by 2
THE DEVELOPMENT OF THE MARKET ECONOMY IN COLONIAL MASSACHUSETTS
Weiss, R. S. (1981) · ScholarWorks@UMassAmherst (University of Massachusetts Amherst) · Cited by 2
Alcohol and Drug Use Disorders
Baca-Atlas, M., Baca-Atlas, S. N., & Fedoriw, K. B. (2023) · Springer eBooks · doi:10.1007/978-3-031-29171-5_6 · Cited by 1
A qualitative study of interest in and preferences for potential medications to treat methamphetamine use disorder
Wagner, K. D., Marks, C., Fiuty, P., Harding, R. W., & Page, K. A. (2023) · Addiction Science & Clinical Practice · doi:10.1186/s13722-023-00401-1 · Cited by 1
Emergency Room Utilization and Methamphetamine Overdose Symptoms Among Syringe Services Program Participants in Washington State
Frank, N. D., Banta‐Green, C. J., Guthrie, B. L., Kingston, S., Tinsley, J., Whiteside, L., & Glick, S. N. (2024) · Substance Use & Misuse · doi:10.1080/10826084.2024.2317148 · Cited by 1
The Intersection of Substance Use Disorders and Infectious Diseases in the Emergency Department
Anderson, E. S., & Frazee, B. W. (2024) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2024.02.004 · Cited by 1
Stimulanzien
Bach, P., Stenger, M., & Ersche, K. D. (2024) · Der Nervenarzt · doi:10.1007/s00115-024-01687-5 · Cited by 1
Effects of randomization to buprenorphine or naltrexone for OUD on cannabis use outcomes: A secondary analysis of the X:BOT trial
Shulman, M., Choo, T.-H. J., Ohrtman, K., Pavlicová, M., Rotrosen, J., & Nunes, E. V. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112550 · Cited by 1
Self-citation
Trial protocol of an open-label pilot study of oral naltrexone–bupropion combination pharmacotherapy for the treatment of methamphetamine use disorder (the NABU trial)
Siefried, K. J., Acheson, L. S., Clifford, B., Moller, C. I., Brett, J., Christmass, M. A., Dunlop, A. J., Haber, P., Jutras‐Aswad, D., Lintzeris, N., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-092032 · Cited by 1
Self-citation
Protocol of an open-label safety and feasibility pilot study of ketamine-assisted psychotherapy for methamphetamine use disorder (the KAPPA trial)
Fletcher, K., Ezard, N., Siefried, K. J., Macdonald, H., Acheson, L. S., Bedi, G., Guerin, A. A., Knock, E., Millard, M., May, R., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-092504 · Cited by 1
Speed and smoking kill: A time-varying survival analysis linking methamphetamine use, cigarette smoking, and mortality in sexual minority men
Yi, G. T., Javanbakht, M., Rosen, A. D., Gorbach, P. M., Clark, J. L., & SHOPTAW, S. J. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.104874 · Cited by 1
Self-citation
Linkage to hepatitis C virus care in a binational cohort study of People who inject drugs on the U.S.-Mexico border
Go, B.-S., Abramovitz, D. A., Artamónova, I., Vera, A., Martin, N. K., Rangel, G., Ramers, C. B., Tweeten, S., Tilghman, W., Strathdee, S. A., et al. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.104899 · Cited by 1
A Treatment Mobile App for Sexual Minority Men Who Use Methamphetamine Demonstrates Reductions in Methamphetamine Use and HIV Sexual Risk Behaviors: Getting Off
Reback, C. J., Lin, C., Li, M. J., Fletcher, J. B., & Mata, R. P. (2025) · AIDS and Behavior · doi:10.1007/s10461-025-04816-6 · Cited by 1
Theta burst stimulation (TBS) in methamphetamine use disorder: a meta-analysis and systematic review
Rakesh, G., Adams, T. G., Ballard, D. H., McLouth, C. J., & Rush, C. R. (2025) · Journal of Addictive Diseases · doi:10.1080/10550887.2025.2541165 · Cited by 1
Implementation of contingency management with women engaging in polysubstance use
Ward, K., Carrico, A. W., Vader, D. T., Moore, R. H., Amico, K. R., Groves, A. K., Bellamy, S. L., Sherman, S. G., Krakower, D., Mazzella, S., et al. (2025) · Addiction Science & Clinical Practice · doi:10.1186/s13722-025-00590-x · Cited by 1
Cocaine craving and use during pharmacotherapy trials for cocaine use disorder: A multi-trajectory analysis
Mojtabai, R., Susukida, R., Farokhnia, M., Nguyen, T. Q., Leggio, L., Bergeria, C. L., Dunn, K. E., & Amin‐Esmaeili, M. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112841 · Cited by 2
Can a participant‐referred ‘study buddy’ increase retention of rural people who use drugs in research? A multi‐site, randomized trial
Young, A. M., Lancaster, K. E., Elman, M., Bielavitz, S., Cook, R., Estadt, A. T., Enderle, M. N., Freeman, E., Lapidus, J., & Korthuis, P. T. (2025) · Addiction · doi:10.1111/add.70250 · Cited by 1
Treatment of Cocaine and Methamphetamine Use Disorders
Wolkowicz, N. R., Schwartz, E. K. C., MacLean, R. R., & Sofuoglu, M. (2025) · Current Addiction Reports · doi:10.1007/s40429-025-00704-0 · Cited by 1
Naltrexone/Bupropion/Mirtazapine Triple Therapy for Treatment-Resistant Methamphetamine Use Disorder: A Case Series
Shariatzadeh, N., & Wakhlu, S. (2026) · Cureus · doi:10.7759/cureus.102744 · Cited by 1
Self-citation
Naltrexone as Pre-exposure Prophylaxis for Unintentional Opioid Overdose in Stimulant Use Disorder: A Case Report
Jaffe, G. A., & Goodstein, D. (2026) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001690 · Cited by 1
National Institute on Drug Abuse (NIDA) clinical trials network (CTN) stimulant use disorder (StUD) task force results: 2024 update
Kittirattanapaiboon, C., SHOPTAW, S. J., Mayes, T. L., Jha, M. K., Ghitza, U. E., & Trivedi, M. H. (2026) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2026.209994 · Cited by 1
Self-citation
Translational medications development for methamphetamine use disorder: A systematic review of preclinical, human laboratory, and clinical research
Johansen, A. N., Smith, M. A., & Stoops, W. W. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100145 · Cited by 1
New Horizons in the Development of Treatments for Substance Use Disorders
Mariani, J. J., & LEVIN, F. R. (2026) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20260362 · Cited by 1
Substance-Related and Addictive Disorders
Grimaldi, J. A., Bodnar, J., Lavin, D., McLaughlin, M. L., Rasimas, J. J., & Ashley, K. B. (2021) · Springer eBooks · doi:10.1007/978-3-030-80665-1_11 · Cited by 1
Alcohol and Methamphetamine Interactions and Co-abuse
Sharpe, A. L., Trzeciak, M., Handa, K., & Beckstead, M. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-92392-1_151 · Cited by 1
Treating stimulant use disorders: still searching for signals
Price, L. H. (2023) · The Brown University Psychopharmacology Update · doi:10.1002/pu.30987 · Cited by 1
A preliminary evaluation of N-acetylcysteine's effects on patient adherence to treatment for cocaine use disorder
Schechter, J., Brown, G. W., & Janda, M. (2023) · Mental Health Clinician · doi:10.9740/mhc.2023.02.004 · Cited by 1
Comparing professional communities: Opioid prescriber networks and Public Health Preparedness Districts
Kaminski, P. C., Perry, B. L., & Green, H. D. (2023) · Harm Reduction Journal · doi:10.1186/s12954-023-00840-8 · Cited by 1
Association of current substance use treatment with future reduced methamphetamine use in an observational cohort of men who have sex with men in Los Angeles
Rosen, A. D., Javanbakht, M., SHOPTAW, S. J., Seamans, M. J., Lloyd‐Smith, J. O., & Gorbach, P. M. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2023.209228 · Cited by 1
Self-citation
Extracorporeal Membrane Oxygenation: Rescue Therapy in Pediatric Bupropion Cardiotoxicity
Olives, T. D., Sweat, C. N., Dorsey-Spitz, L., Bahadori-Esfahani, F., Arens, A. M., Cole, J. B., & Somani, A. (2024) · Journal of Pediatric Intensive Care · doi:10.1055/s-0044-1786769 · Cited by 1
Bupropion in Comorbid Post-Traumatic Stress Disorder and Methamphetamine Use Disorder
Kneebusch, J., & Farhadian, S. (2024) · Journal of Pharmacy Practice · doi:10.1177/08971900241276698 · Cited by 1
Medications for OUD: Extended-Release Naltrexone
Srivastava, A. B. (2025) · Current Addiction Reports · doi:10.1007/s40429-025-00636-9 · Cited by 1
Project RETAIN: Providing Integrated Care for People With HIV Who Use Cocaine
Metsch, L. R., Feaster, D. J., Gooden, L. K., Pan, Y., Parish, C. L., Waldrop, D. G., Rodriguez, A. E., Colasanti, J. A., Castellón, P. C., Armstrong, W. S., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf104 · Cited by 1
Sıçanlarda Bupropion ve Vareniklinin Morfin Yoksunluğu Sendromu Üzerine Etkileri
Yunusoğlu, O., KÖSE, Ç., Özyazgan, S., Shahzadi, A., Demir, B., Önal, B., & Akkan, A. G. (2022) · Abant Medical Journal · doi:10.47493/abantmedj.1120849 · Cited by 1
Insights Into the Complexity of Methamphetamine Actions in the Brain and Periphery in the Face of a 3rd Methamphetamine Abuse Epidemic
Moszczyńska, A. (2021) · Current Neuropharmacology · doi:10.2174/1570159x1912211213145444 · Cited by 1
A new protocol of methamphetamine dependence treatment with taper-up-off treatment of opium tincture, a new hope to cure the methamphetamine addictionPreprint
Dezhakam, H., Dezhakam, A., Dezhakam, S., Dezhakam, A., & Haghighatfard, A. (2023) · Research Square · doi:10.21203/rs.3.rs-2927654/v1 · Cited by 1
Modernizing Withdrawal Management Services
Mocanu, V., Cowan, N., Klimas, J., Ahamad, K., & Wood, E. (2021) · The Canadian Journal of Addiction · doi:10.1097/cxa.0000000000000113
Stimulant-Related Disorders
Boyer, M. W. (2021) · Psychiatry update · doi:10.1007/978-3-030-86430-9_9
Acute intoxication following massive bupropion sniffing: A case report
Sartori, S., Brilli, V., Lanzi, C., Pratticò, L., Sarcoli, E., Milia, M. G., Gambassi, F., & Mannaioni, G. (2021) · Emergency Care Journal · doi:10.4081/ecj.2021.10037
Alcohol and Methamphetamine Interactions and Co-abuse
Sharpe, A. L., Trzeciak, M., Handa, K., & Beckstead, M. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-67928-6_151-1
Methamphetamine Use Among Sexual Minority Men
Lodge, W., Biello, K. B., Valente, P. K., & Mimiaga, M. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-67928-6_109-1

Authors: Trivedi, M. H., Walker, R., Ling, W., dela Cruz, A., Sharma, G., Carmody, T., Ghitza, U. E., Wahle, A., Kim, M., Shores-Wilson, K., Sparenborg, S., Coffin, P., Schmitz, J., Wiest, K., Bart, G., Sonne, S. C., Wakhlu, S., Rush, A. J., Nunes, E. V., & Shoptaw, S.
Affiliations: Texas Tech University (US)
From the Peter O’Donnell Jr. Brain Institute at the University of Texas Southwestern Medical Center (M.H.T.) and the University of Texas Southwestern Medical Center (R.W., A.C., T.C., M.K., K.S.-W., S.W.), Dallas, the University of Texas Health Science Center at Houston, Houston (J.S.), and Texas Tech University, Permian Basin, Odessa (A.J.R.); the University of California, Los Angeles, Los Angeles (W.L., S. Shoptaw); the Emmes Company, Rockville (G.S., A.W.), and the National Institute on Drug...
ORCID: Trivedi, Madhukar H.
Walker, Robrina
Ling, Walter
Sharma, Gaurav
Carmody, Thomas
Ghitza, Udi E.
Coffin, Phillip
Schmitz, Joy
Wiest, Katharina
Bart, Gavin
Rush, A. John
Nunes, Edward V.
Shoptaw, Steven
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2021-01-14
Volume: 384
Issue: 2
Pages: 140-153
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2020214
PMC: PMC8111570
OpenAlex: W3118735640
Cited by: 281
References: 30
Citations by year: 2026: 49 · 2025: 45 · 2024: 45 · 2023: 63 · 2022: 43 · 2021: 35
FWCI: 33.49
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: U.S. Department of Health and Human Services (Contract No. HHSN271201500065C; HHSN271201400028C)
National Institute on Drug Abuse (UG1DA020024; UG1DA013035; UG1DA040316; UG1DA013727)
Topics: Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords: methamphetamine dependence, naltrexone, bupropion, combination pharmacotherapy, treatment response, adverse events, drug addiction treatment, urine drug testing, relapse prevention, opioid antagonists, antidepressants, stimulant use disorder, treatment efficacy and safety, serious adverse events
MeSH terms: Administration, Oral, Adolescent, Adult, Aged, Delayed-Action Preparations, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Injections, Male, Methamphetamine, Middle Aged, Naltrexone, Narcotic Antagonists, Bupropion, Amphetamine-Related Disorders, Medication Adherence, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Bupropion and Naltrexone in Methamphetamine Use Disorder

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks